1
|
Feng Y, Pannem S, Hodge S, Rounds C, Tichauer KM, Paulsen KD, Samkoe KS. Quantitative pharmacokinetic and biodistribution studies for fluorescent imaging agents. BIOMEDICAL OPTICS EXPRESS 2024; 15:1861-1877. [PMID: 38495714 PMCID: PMC10942698 DOI: 10.1364/boe.504878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 12/02/2023] [Accepted: 01/22/2024] [Indexed: 03/19/2024]
Abstract
Pharmacokinetics and biodistribution studies are essential for characterizing fluorescent agents in vivo. However, few simple methods based on fluorescence imaging are available that account for tissue optical properties and sample volume differences. We describe a method for simultaneously quantifying mean fluorescence intensity of whole blood and homogenized tissues in glass capillary tubes for two fluorescent agents, ABY-029 and IRDye 680LT, using wide-field imaging and tissue-specific calibration curves. All calibration curves demonstrated a high degree of linearity with mean R2 = 0.99 ± 0.01 and RMSE = 0.12 ± 0.04. However, differences between linear regressions indicate that tissue-specific calibration curves are required for accurate concentration recovery. The lower limit of quantification (LLOQ) for all samples tested was determined to be < 0.3 nM for ABY-029 and < 0.4 nM for IRDye 680LT.
Collapse
Affiliation(s)
- Yichen Feng
- Geisel School of Medicine, Dartmouth College, 1 Rope Ferry Road, Hanover, NH 03755, USA
| | - Sanjana Pannem
- Thayer School of Engineering, Dartmouth College, 15 Thayer Drive, Hanover, NH 03755, USA
| | - Sassan Hodge
- Thayer School of Engineering, Dartmouth College, 15 Thayer Drive, Hanover, NH 03755, USA
| | - Cody Rounds
- Department of Biomedical Engineering, Illinois Institute of Technology, 10 West 35 Street, Chicago, IL 60616, USA
| | - Kenneth M. Tichauer
- Department of Biomedical Engineering, Illinois Institute of Technology, 10 West 35 Street, Chicago, IL 60616, USA
| | - Keith D. Paulsen
- Thayer School of Engineering, Dartmouth College, 15 Thayer Drive, Hanover, NH 03755, USA
| | - Kimberley S. Samkoe
- Geisel School of Medicine, Dartmouth College, 1 Rope Ferry Road, Hanover, NH 03755, USA
- Thayer School of Engineering, Dartmouth College, 15 Thayer Drive, Hanover, NH 03755, USA
| |
Collapse
|
2
|
Torres VC, Hodge S, Levy JJ, Vaickus LJ, Chen EY, LeBouef M, Samkoe KS. Paired-agent imaging as a rapid en face margin screening method in Mohs micrographic surgery. Front Oncol 2023; 13:1196517. [PMID: 37427140 PMCID: PMC10325620 DOI: 10.3389/fonc.2023.1196517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 06/05/2023] [Indexed: 07/11/2023] Open
Abstract
Background Mohs micrographic surgery is a procedure used for non-melanoma skin cancers that has 97-99% cure rates largely owing to 100% margin analysis enabled by en face sectioning with real-time, iterative histologic assessment. However, the technique is limited to small and aggressive tumors in high-risk areas because the histopathological preparation and assessment is very time intensive. To address this, paired-agent imaging (PAI) can be used to rapidly screen excised specimens and identify tumor positive margins for guided and more efficient microscopic evaluation. Methods A mouse xenograft model of human squamous cell carcinoma (n = 8 mice, 13 tumors) underwent PAI. Targeted (ABY-029, anti-epidermal growth factor receptor (EGFR) affibody molecule) and untargeted (IRDye 680LT carboxylate) imaging agents were simultaneously injected 3-4 h prior to surgical tumor resection. Fluorescence imaging was performed on main, unprocessed excised specimens and en face margins (tissue sections tangential to the deep margin surface). Binding potential (BP) - a quantity proportional to receptor concentration - and targeted fluorescence signal were measured for each, and respective mean and maximum values were analyzed to compare diagnostic ability and contrast. The BP and targeted fluorescence of the main specimen and margin samples were also correlated with EGFR immunohistochemistry (IHC). Results PAI consistently outperformed targeted fluorescence alone in terms of diagnostic ability and contrast-to-variance ratio (CVR). Mean and maximum measures of BP resulted in 100% accuracy, while mean and maximum targeted fluorescence signal offered 97% and 98% accuracy, respectively. Moreover, maximum BP had the greatest average CVR for both main specimen and margin samples (average 1.7 ± 0.4 times improvement over other measures). Fresh tissue margin imaging improved similarity with EGFR IHC volume estimates compared to main specimen imaging in line profile analysis; and margin BP specifically had the strongest concordance (average 3.6 ± 2.2 times improvement over other measures). Conclusions PAI was able to reliably distinguish tumor from normal tissue in fresh en face margin samples using the single metric of maximum BP. This demonstrated the potential for PAI to act as a highly sensitive screening tool to eliminate the extra time wasted on real-time pathological assessment of low-risk margins.
Collapse
Affiliation(s)
- Veronica C. Torres
- Thayer School of Engineering, Dartmouth College, Hanover, NH, United States
| | - Sassan Hodge
- Thayer School of Engineering, Dartmouth College, Hanover, NH, United States
| | - Joshua J. Levy
- Geisel School of Medicine, Dartmouth College, Hanover, NH, United States
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States
- Department of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States
- Quantitative Biomedical Sciences, Geisel School of Medicine, Dartmouth College, Hanover, NH, United States
- Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NH, United States
| | - Louis J. Vaickus
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States
| | - Eunice Y. Chen
- Geisel School of Medicine, Dartmouth College, Hanover, NH, United States
- Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States
| | - Matthew LeBouef
- Geisel School of Medicine, Dartmouth College, Hanover, NH, United States
- Department of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States
| | | |
Collapse
|
3
|
Wang C, Xu X, Hodge S, Chen EY, Hoopes PJ, Tichauer KM, Samkoe KS. Identification of a Suitable Untargeted Agent for the Clinical Translation of ABY-029 Paired-Agent Imaging in Fluorescence-Guided Surgery. Mol Imaging Biol 2023; 25:97-109. [PMID: 34642897 PMCID: PMC9413473 DOI: 10.1007/s11307-021-01642-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 08/05/2021] [Accepted: 08/12/2021] [Indexed: 11/24/2022]
Abstract
PURPOSE Non-specific uptake and retention of molecular targeted agents and heterogeneous tissue optical properties diminish the ability to differentiate between tumor and normal tissues using molecular targeted fluorescent agents. Paired-agent imaging (PAI) can increase the diagnostic ability to detect tumor tissue by mitigating these non-specific effects and providing true molecular contrast by co-administration of an untargeted control imaging agent with a targeted agent. This study evaluates the suitability of available clinically translatable untargeted agents for the translation of PAI in fluorescence-guided surgery using an affibody-based targeted imaging agent (ABY-029). EXPERIMENTAL DESIGN: Three untargeted agents that fluoresce near 700 nm and exhibit good clinical safety profiles (methylene blue, IRDye 700DX, and IRDye 680LT) were tested in combination with the clinically tested IRDye 800CW-labeled anti-epidermal growth factor receptor (EGFR) affibody molecule, ABY-029 (eIND 122,681). Properties of the untargeted agent important for human use and integrity of PAI were tested: (1) plasma protein binding; (2) fluorescence signal linearity in in vitro whole blood dilution; (3) in vivo pharmacokinetic matching to targeted agent in negative control tissue; and (4) in vivo diagnostic accuracy of PAI vs single agent imaging (SAI) of ABY-029 alone in orthotopic oral head and neck squamous cell carcinomas. RESULTS IRDye 680LT outperformed IRDye 700DX and methylene blue with the highest signal linearity (R2 = 0.9998 ± 0.0002, 0.9995 ± 0.0004, 0.91 ± 0.02, respectively), the highest fluorescence yield in whole blood at 1 μM (104.42 ± 0.05, 103.68 ± 0.09, 101.9 ± 0.2, respectively), and the most closely matched ABY-029 pharmacokinetics in EGFR-negative tissues (binding potential error percentage = 0.31% ± 0.37%, 10.25% ± 1.30%, and 8.10% ± 5.37%, respectively). The diagnostic ability of PAI with ABY-029 and IRDye 680LT outperformed conventional SAI with an area-under-the-receiver-operating-characteristic curve (AUC) value of 0.964 vs. 0.854, and 0.978 vs. 0.925 in the Odyssey scanning system and Pearl wide field imaging system, respectively. CONCLUSION PAI is a highly promising methodology for increasing detection of tumors in fluorescence-guided surgery. Although not yet clinically approved, IRDye 680LT demonstrates promise as an untargeted agent when paired with ABY-029. The clinical translation of PAI to maximize tumor excision, while minimizing normal tissue removal, could improve both patient survival and life quality.
Collapse
Affiliation(s)
- Cheng Wang
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Xiaochun Xu
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Sassan Hodge
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Eunice Y Chen
- Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - P Jack Hoopes
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.,Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - Kenneth M Tichauer
- Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA
| | - Kimberley S Samkoe
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. .,Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
| |
Collapse
|
4
|
Wang C, Xu X, Folaron M, Gunn JR, Hodge S, Chen EY, Hoopes PJ, Tichauer KM, Samkoe KS. Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols. Mol Imaging Biol 2023; 25:110-121. [PMID: 34651290 PMCID: PMC9527767 DOI: 10.1007/s11307-021-01656-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 06/16/2021] [Accepted: 07/18/2021] [Indexed: 11/26/2022]
Abstract
PURPOSE The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targeted agents and the variance of fluorescence signal. Paired-agent imaging (PAI) employs co-administration of an untargeted imaging agent with a molecular targeted agent, providing a normalization factor to minimize nonspecific and varied signals. The resulting measured binding potential is quantitative and equivalent to in vivo immunohistochemistry of the target protein. This study demonstrates that PAI improves the accuracy of tumor-to-healthy tissue discrimination compared to single-agent imaging for in vivo FGS. PROCEDURES PAI using a fluorescent anti-epidermal growth factor receptor (EGFR) affibody molecule (ABY-029, eIND 122,681) with untargeted IRDye 700DX carboxylate was compared to ABY-029 alone in an oral squamous cell carcinoma xenograft mouse model at 3 h after dye administration (n = 30). RESULTS PAI significantly enhanced tumor discrimination, as compared to ABY-029 alone in low EGFR-expressing tumors and highly heterogeneous populations including multiple cell lines with varying expression (diagnostic accuracy: 0.908 vs. 0.854 and 0.908 vs. 0.822; and ROC curve AUC: 0.963 vs. 0.909 and 0.957 vs. 0.909, respectively) indicating a potential for universal FGS image thresholds to determine surgical margins. In addition, PAI achieved significantly higher diagnostic ability than ABY-029 alone 0.25-5-h post injection and exhibited a stronger correlation to EGFR expression heterogeneity. CONCLUSION The quantitative receptor delineation of PAI promises to improve the surgical therapeutic index of cancer resection in a clinically relevant timeline.
Collapse
Affiliation(s)
- Cheng Wang
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Xiaochun Xu
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Margaret Folaron
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Jason R Gunn
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Sassan Hodge
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
| | - Eunice Y Chen
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
- Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - P Jack Hoopes
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
- Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - Kenneth M Tichauer
- Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA
| | - Kimberley S Samkoe
- Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
- Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
- Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
| |
Collapse
|
5
|
Meng B, Sadeghipour N, Folaron MR, Strawbridge RR, Samkoe KS, Tichauer KM, Davis SC. Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging. Mol Imaging Biol 2021; 24:23-30. [PMID: 34286423 PMCID: PMC8760219 DOI: 10.1007/s11307-021-01629-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 06/16/2021] [Accepted: 06/21/2021] [Indexed: 12/02/2022]
Abstract
Purpose The ability to noninvasively quantify receptor availability (RA) in solid tumors is an aspirational goal of molecular imaging, often challenged by the influence of non-specific accumulation of the contrast agent. Paired-agent imaging (PAI) techniques aim to compensate for this effect by imaging the kinetics of a targeted agent and an untargeted isotype, often simultaneously, and comparing the kinetics of the two agents to estimate RA. This is usually accomplished using two spectrally distinct fluorescent agents, limiting the technique to superficial tissues and/or preclinical applications. Applying the approach in humans using conventional imaging modalities is generally infeasible since most modalities are unable to routinely image multiple agents simultaneously. We examine the ability of PAI to be implemented in a cross-modality paradigm, in which the targeted and untargeted agent kinetics are imaged with different modalities and used to recover receptor availability. Procedures Eighteen mice bearing orthotopic brain tumors were administered a solution containing three contrast agents: (1) a fluorescent agent targeted to epidermal growth factor receptor (EGFR), (2) an untargeted fluorescent isotype, and (3) a gadolinium-based contrast agent (GBCA) for MRI imaging. The kinetics of all three agents were imaged for 1 h after administration using an MRI-coupled fluorescence tomography system. Paired-agent receptor availability was computed using (1) the conventional all-optical approach using the targeted and untargeted optical agent images and (2) the cross-modality approach using the targeted optical and untargeted MRI-GBCA images. Receptor availability estimates between the two methods were compared. Results Receptor availability values using the cross-modality approach were highly correlated to the conventional, single-modality approach (r = 0.94; p < 0.00001). Conclusion These results suggest that cross-modality paired-agent imaging for quantifying receptor availability is feasible. Ultimately, cross-modality paired-agent imaging could facilitate rapid, noninvasive receptor availability quantification in humans using hybrid clinical imaging modalities. Supplementary Information The online version contains supplementary material available at 10.1007/s11307-021-01629-6.
Collapse
Affiliation(s)
- Boyu Meng
- Thayer School of Engineering, Dartmouth College, 03755, Hanover, NH, USA
| | - Negar Sadeghipour
- Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA
| | - Margaret R Folaron
- Thayer School of Engineering, Dartmouth College, 03755, Hanover, NH, USA
| | | | - Kimberley S Samkoe
- Thayer School of Engineering, Dartmouth College, 03755, Hanover, NH, USA.,Geisel School of Medicine, Dartmouth College, 03755, Hanover, NH, USA
| | - Kenneth M Tichauer
- Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA
| | - Scott C Davis
- Thayer School of Engineering, Dartmouth College, 03755, Hanover, NH, USA.
| |
Collapse
|
6
|
Tichauer KM, Wang C, Xu X, Samkoe KS. Task-based evaluation of fluorescent-guided cancer surgery as a means of identifying optimal imaging agent properties in the context of variability in tumor- and healthy-tissue physiology. PROCEEDINGS OF SPIE--THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING 2020; 11222. [PMID: 33568879 DOI: 10.1117/12.2546700] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Fluorescent molecular-guided surgery (FGS) is at a tipping point in terms of clinical approval and adoption in a number cancer applications, with ongoing phase 0 and phase 1 clinical trials being carried out in a wide range of cancers using a wide range of agents. The pharmacokinetics of each of these agents and the physiology of these cancers can differ vastly on a patient-to-patient basis, bringing to question: how can one fairly compare different methodologies (defined as the combination of imaging agent, system, and protocol) and how can existing methodologies be further optimized? To this point, little methodology comparison has been carried out, and the majority of FGS optimization has concerned system development-on the level of maximizing signal-to-noise, dynamic detection range, and sensitivity-independently from traditional agent development-in terms of fluorophore brightness, toxicity, solubility, and binding affinity and specificity. Here we propose an inclusion of tumor and healthy tissue physiology (blood flow, vascular permeability, specific and nonspecific binding sites, extracellular matrix, interstitial pressure, etc…) variability into the optimization process and re-establish well-described task-based metrics for methodology optimization and comparing quality of one methodology to another. Two salient conclusions were identified: (1) contrast-to-background variability is a simple metric that correlates with difficult-to-carry-out task-based metrics for comparing methodologies, and (2) paired-agent imaging protocols offer unique advantages over single-imaging-agent studies for mitigating confounding tumor and background physiology variability.
Collapse
Affiliation(s)
| | - Cheng Wang
- Thayer School of Engineering, Dartmouth College, Hanover, NH
| | - Xiaochun Xu
- Department of Surgery, Dartmouth Geisel School of Medicine, Hanover, NH
| | - Kimberley S Samkoe
- Thayer School of Engineering, Dartmouth College, Hanover, NH.,Department of Surgery, Dartmouth Geisel School of Medicine, Hanover, NH
| |
Collapse
|
7
|
Singh N, Kumar P, Riaz U. Applications of near infrared and surface enhanced Raman scattering techniques in tumor imaging: A short review. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2019; 222:117279. [PMID: 31234091 DOI: 10.1016/j.saa.2019.117279] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 06/08/2019] [Accepted: 06/15/2019] [Indexed: 06/09/2023]
Abstract
Imaging technologies play a vital role in clinical oncology and have undergone massive growth over the past few decades. Research in the field of tumor imaging and biomedical diagnostics requires early detection of physiological alterations so as to provide curative treatment in real time. The objective of this review is to provide an insight about near infrared fluorescence (NIRF) and surface enhanced Raman scattering (SERS) imaging techniques that can be used to expand their capabilities for the early detection and diagnosis of cancer cells. Basic setup, principle and working of the instruments has been provided and common NIRF imaging agents as well as SERS tags are also discussed besides the analytical advantages/disadvantages of these techniques. This review can help researchers working in the field of molecular imaging to design cost effective fluorophores and SERS tags to overcome the limitations of both NIRF as well as SERS imaging technologies.
Collapse
Affiliation(s)
- Neetika Singh
- Materials Research Laboratory, Department of Chemistry, Jamia Millia Islamia, New Delhi 110025, India; Advanced Instrumentation Research Facility, Jawaharlal Nehru University, New Delhi 110067, India
| | - Prabhat Kumar
- Materials Research Laboratory, Department of Chemistry, Jamia Millia Islamia, New Delhi 110025, India; Advanced Instrumentation Research Facility, Jawaharlal Nehru University, New Delhi 110067, India
| | - Ufana Riaz
- Materials Research Laboratory, Department of Chemistry, Jamia Millia Islamia, New Delhi 110025, India; Advanced Instrumentation Research Facility, Jawaharlal Nehru University, New Delhi 110067, India.
| |
Collapse
|
8
|
Samkoe KS, Schultz E, Solanki A, Wang L, Korber J, Tichauer KM, Gibbs SL. Simultaneous extracellular and intracellular quantification of EGFR using paired-agent imaging in an in ovo tumor model. PROCEEDINGS OF SPIE--THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING 2019; 10859. [PMID: 32296254 DOI: 10.1117/12.2510778] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Quantification of protein concentrations is often a static and tissue destructive technique. Paired-agent imaging (PAI) using matched targeted and untargeted agents has been established as a dynamic method for quantifying the extracellular domain of epidermal growth factor receptor (EGFR) in vivo in a variety of tumor lines. Here we extend the PAI model to simultaneously quantify the extracellular and intracellular regions of EGFR using novel cell membrane permeable fluorescent small molecules, TRITC-erlotinib (targeted) and BODIPY-N-erlotinib (non-binding control isoform) synthesized in house. An EGFR overexpressing squamous cell carcinoma cell xenograft tumor, A431, was implanted on the chorioallantoic membrane (CAM) of the embryonated chicken egg. In total six fluorescent molecules were administered and monitored over 1 h using multi-spectral imaging. EGFR concentrations were determined using both extracellular and intracellular PAI methods. The fluorescent molecules used for extracellular PAI were ABY-029, an anti-EGFR Affibody molecule conjugated to IRDye 800CW, and a Control Imaging Agent Affibody molecule conjugated to IRDye 680RD. The intracellular PAI (iPAI) fluorescent molecules were cell membrane penetrating TRITC-erlotinib, BODIPY-N-erlotinb, and BODIPY TR carboxylate, as well as cell membrane impermeant control agent, Alexa Fluor 647 carboxylate. Results from simultaneous imaging of both the extracellular and intracellular binding domains of EGFR indicate that concentrations of intracellular EGFR are higher than extracellular. This is anticipated as EGFR exists in two distinct populations in cells, cell membrane bound and internalized, activated protein. iPAI is a promising new method for quantifying intracellular proteins in a rapid tumor model on the chicken CAM.
Collapse
Affiliation(s)
- Kimberley S Samkoe
- Geisel School of Medicine, Dartmouth College, Hanover, NH 03755.,Department of Surgery, Dartmouth-Hitchcock, Lebanon, NH, 03756
| | - Emily Schultz
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, 60616
| | - Allison Solanki
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, 60616
| | - Lei Wang
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, 60616
| | - Jesse Korber
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, 60616
| | - Kenneth M Tichauer
- Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR, 97201
| | - Summer L Gibbs
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, 60616
| |
Collapse
|
9
|
Samkoe KS, Park Y, Marra K, Chen EY, Tichauer KM. Paired-agent imaging for detection of head and neck cancers. PROCEEDINGS OF SPIE--THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING 2019; 10853. [PMID: 31686720 DOI: 10.1117/12.2510897] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Head and neck cancers overwhelmingly overexpress epidermal growth factor receptor (EGFR). This overexpression has been utilized for head and neck cancers using molecular targeted agents for therapy and cancer cell detection. Significant progress has been made in using EGFR-targeted fluorescent antibody and Affibody molecule agents for fluorescent guided surgery in head and neck cancers. Although success in achieving tumor-to-background ratio of 3-5 have been achieved, the field is limited by the non-specific fluorescence in normal tissues as well as EGFR specific fluorescence in the oral cavity. We propose that paired-agent imaging (PAI) could improve the contrast between tumor and normal tissue by removing the fluorescent signal arising from non-specific binding. Here, ABY-029 - an anti-EGFR Affibody molecule labeled with IRDye 800CW - and IRDye 680RD conjugated to Affibody Control Imaging Agent molecule (IR680-Affctrl) are used as targeted and untargeted control agents, respectively, in a panel of head and neck squamous cell carcinomas (HNSCC) to test the ability of PAI to increase tumor detection. Initial results demonstrate that binding potential, a value proportional to receptor concentration, correlates well to EGFR expression but experimental limitations prevented pixel-by-pixel analysis that was desired. Although promising, a more rigorous and well-defined experimental protocol is required to align ex vivo EGFR immunohistochemistry with in vivo binding potential and fluorescence intensity. Additionally, a new set of paired-agents, ABY-029 and IRDye 700DX, are successfully tested in naïve mice and will be carried forward for clinical translation.
Collapse
Affiliation(s)
- Kimberley S Samkoe
- Geisel School of Medicine, Dartmouth College, Hanover, NH 03755.,Department of Surgery, Dartmouth-Hitchcock, Lebanon, NH, 03756
| | | | - Kayla Marra
- Thayer School of Engineering at Dartmouth, Lebanon, NH, 03755
| | - Eunice Y Chen
- Geisel School of Medicine, Dartmouth College, Hanover, NH 03755
| | - Kenneth M Tichauer
- Department of Biomedical Engineering, llinois Institute of Technology, Chicago, Illinois, 60616
| |
Collapse
|
10
|
Pogue BW, Rosenthal EL, Achilefu S, van Dam GM. Perspective review of what is needed for molecular-specific fluorescence-guided surgery. JOURNAL OF BIOMEDICAL OPTICS 2018; 23:1-9. [PMID: 30291698 PMCID: PMC6210787 DOI: 10.1117/1.jbo.23.10.100601] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 09/07/2018] [Indexed: 05/21/2023]
Abstract
Molecular image-guided surgery has the potential for translating the tools of molecular pathology to real-time guidance in surgery. As a whole, there are incredibly positive indicators of growth, including the first United States Food and Drug Administration clearance of an enzyme-biosynthetic-activated probe for surgery guidance, and a growing number of companies producing agents and imaging systems. The strengths and opportunities must be continued but are hampered by important weaknesses and threats within the field. A key issue to solve is the inability of macroscopic imaging tools to resolve microscopic biological disease heterogeneity and the limitations in microscopic systems matching surgery workflow. A related issue is that parsing out true molecular-specific uptake from simple-enhanced permeability and retention is hard and requires extensive pathologic analysis or multiple in vivo tests, comparing fluorescence accumulation with standard histopathology and immunohistochemistry. A related concern in the field is the over-reliance on a finite number of chosen preclinical models, leading to early clinical translation when the probe might not be optimized for high intertumor variation or intratumor heterogeneity. The ultimate potential may require multiple probes, as are used in molecular pathology, and a combination with ultrahigh-resolution imaging and image recognition systems, which capture the data at a finer granularity than is possible by the surgeon. Alternatively, one might choose a more generalized approach by developing the tracer based on generic hallmarks of cancer to create a more "one-size-fits-all" concept, similar to metabolic aberrations as exploited in fluorodeoxyglucose - positron emission tomography (FDG-PET) (i.e., Warburg effect) or tumor acidity. Finally, methods to approach the problem of production cost minimization and regulatory approvals in a manner consistent with the potential revenue of the field will be important. In this area, some solid steps have been demonstrated in the use of fluorescent labeling commercial antibodies and separately in microdosing studies with small molecules.
Collapse
Affiliation(s)
- Brian W. Pogue
- Dartmouth College, Thayer School of Engineering and Department of Surgery, Geisel School of Medicine, Hanover, New Hampshire, United States
- Address all correspondence to: Brian W. Pogue, E-mail:
| | - Eben L. Rosenthal
- Stanford University School of Medicine, Department of Otolaryngology and Head and Neck Surgery, Stanford, California, United States
| | - Samuel Achilefu
- Washington University in St. Louis, Department of Radiology, St. Louis, Missouri, United States
| | - Gooitzen M. van Dam
- University Medical Center Groningen, Department of Surgery, Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands
| |
Collapse
|
11
|
Sadeghipour N, Davis SC, Tichauer KM. Quantifying cancer cell receptors with paired-agent fluorescent imaging: a novel method to account for tissue optical property effects. PROCEEDINGS OF SPIE--THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING 2018; 10497. [PMID: 30220772 DOI: 10.1117/12.2290631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Dynamic fluorescence imaging approaches can be used to estimate the concentration of cell surface receptors in vivo. Kinetic models are used to generate the final estimation by taking the targeted imaging agent concentration as a function of time. However, tissue absorption and scattering properties cause the final readout signal to be on a different scale than the real fluorescent agent concentration. In paired-agent imaging approaches, simultaneous injection of a suitable control imaging agent with a targeted one can account for non-specific uptake and retention of the targeted agent. Additionally, the signal from the control agent can be a normalizing factor to correct for tissue optical property differences. In this study, the kinetic model used for paired-agent imaging analysis (i.e., simplified reference tissue model) is modified and tested in simulation and experimental data in a way that accounts for the scaling correction within the kinetic model fit to the data to ultimately extract an estimate of the targeted biomarker concentration.
Collapse
Affiliation(s)
- Negar Sadeghipour
- Department of Biomedical Engineering, Illinois Institute of Technology, 3255 S Dearborn St., Chicago, IL USA 60616
| | - Scott C Davis
- Thayer School of Engineering, Dartmouth College, 14 Engineering Dr., Hanover, NH USA 03755-8001
| | - Kenneth M Tichauer
- Department of Biomedical Engineering, Illinois Institute of Technology, 3255 S Dearborn St., Chicago, IL USA 60616
| |
Collapse
|
12
|
Sadeghipour N, Davis SC, Tichauer KM. Correcting for targeted and control agent signal differences in paired-agent molecular imaging of cancer cell-surface receptors. JOURNAL OF BIOMEDICAL OPTICS 2018; 23:1-11. [PMID: 29931837 PMCID: PMC6013418 DOI: 10.1117/1.jbo.23.6.066004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Accepted: 05/31/2018] [Indexed: 05/05/2023]
Abstract
Paired-agent kinetic modeling protocols provide one means of estimating cancer cell-surface receptors with in vivo molecular imaging. The protocols employ the coadministration of a control imaging agent with one or more targeted imaging agent to account for the nonspecific uptake and retention of the targeted agent. These methods require the targeted and control agent data be converted to equivalent units of concentration, typically requiring specialized equipment and calibration, and/or complex algorithms that raise the barrier to adoption. This work evaluates a kinetic model capable of correcting for targeted and control agent signal differences. This approach was compared with an existing simplified paired-agent model (SPAM), and modified SPAM that accounts for signal differences by early time point normalization of targeted and control signals (SPAMPN). The scaling factor model (SPAMSF) outperformed both SPAM and SPAMPN in terms of accuracy and precision when the scale differences between targeted and imaging agent signals (α) were not equal to 1, and it matched the performance of SPAM for α = 1. This model could have wide-reaching implications for quantitative cancer receptor imaging using any imaging modalities, or combinations of imaging modalities, capable of concurrent detection of at least two distinct imaging agents (e.g., SPECT, optical, and PET/MR).
Collapse
Affiliation(s)
- Negar Sadeghipour
- Illinois Institute of Technology, Biomedical Engineering, Chicago, Illinois, United States
| | - Scott C. Davis
- Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, United States
| | - Kenneth M. Tichauer
- Illinois Institute of Technology, Biomedical Engineering, Chicago, Illinois, United States
- Address all correspondence to: Kenneth M. Tichauer, E-mail:
| |
Collapse
|
13
|
Scussolini M, Garbarino S, Piana M, Sambuceti G, Caviglia G. Reference Tissue Models for FDG-PET Data: Identifiability and Solvability. IEEE TRANSACTIONS ON RADIATION AND PLASMA MEDICAL SCIENCES 2018. [DOI: 10.1109/trpms.2018.2801029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
14
|
Weaver JB, Shi Y, Ness DB, Khurshid H, Samia ACS. Sensitivity Limits for in vivo ELISA Measurements of Molecular Biomarker Concentrations. INTERNATIONAL JOURNAL ON MAGNETIC PARTICLE IMAGING 2017; 3. [PMID: 34307836 PMCID: PMC8302994 DOI: 10.18416/ijmpi.2017.1706003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The extremely high sensitivity that has been suggested for magnetic particle imaging has its roots in the unique signal produced by the nanoparticles at the frequencies of the harmonics of the drive field. That sensitivity should be translatable to other methods that utilize magnetic nanoparticle probes, specifically towards magnetic nanoparticle spectroscopy that is used to measure molecular biomarker concentrations for an “in vivo ELISA” assay approach. In this paper, we translate the predicted sensitivity of magnetic particle imaging into a projected sensitivity limit for in vivo ELISA. The simplifying assumptions adopted are: 1) the limiting noise in the detection system is equivalent to the minimum detectable mass of nanoparticles; 2) the nanoparticle’s signal arising from Brownian relaxation is completely eliminated by the molecular binding event, which can be accomplished by binding the nanoparticle to something so massive that it can no longer physically rotate and is large enough that Neel relaxation is minimal. Given these assumptions, the equation for the minimum concentration of molecular biomarker we should be able to detect is obtained and the in vivo sensitivity is estimated to be in the attomolar to zeptomolar range. Spectrometer design and nonspecific binding are the technical limitations that need to be overcome to achieve the theoretical limit presented.
Collapse
Affiliation(s)
- John B Weaver
- Department of Radiology, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.,Department of Physics, Dartmouth College, Hanover, NH, USA.,Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
| | - Yinpeng Shi
- Department of Radiology, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - Dylan B Ness
- Department of Radiology, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - Hafsa Khurshid
- Department of Radiology, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | | |
Collapse
|
15
|
Sadeghipour N, Davis SC, Tichauer KM. Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions. Phys Med Biol 2016; 62:394-414. [PMID: 27997381 DOI: 10.1088/1361-6560/62/2/394] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
New precision medicine drugs oftentimes act through binding to specific cell-surface cancer receptors, and thus their efficacy is highly dependent on the availability of those receptors and the receptor concentration per cell. Paired-agent molecular imaging can provide quantitative information on receptor status in vivo, especially in tumor tissue; however, to date, published approaches to paired-agent quantitative imaging require that only 'trace' levels of imaging agent exist compared to receptor concentration. This strict requirement may limit applicability, particularly in drug binding studies, which seek to report on a biological effect in response to saturating receptors with a drug moiety. To extend the regime over which paired-agent imaging may be used, this work presents a generalized simplified reference tissue model (GSRTM) for paired-agent imaging developed to approximate receptor concentration in both non-receptor-saturated and receptor-saturated conditions. Extensive simulation studies show that tumor receptor concentration estimates recovered using the GSRTM are more accurate in receptor-saturation conditions than the standard simple reference tissue model (SRTM) (% error (mean ± sd): GSRTM 0 ± 1 and SRTM 50 ± 1) and match the SRTM accuracy in non-saturated conditions (% error (mean ± sd): GSRTM 5 ± 5 and SRTM 0 ± 5). To further test the approach, GSRTM-estimated receptor concentration was compared to SRTM-estimated values extracted from tumor xenograft in vivo mouse model data. The GSRTM estimates were observed to deviate from the SRTM in tumors with low receptor saturation (which are likely in a saturated regime). Finally, a general 'rule-of-thumb' algorithm is presented to estimate the expected level of receptor saturation that would be achieved in a given tissue provided dose and pharmacokinetic information about the drug or imaging agent being used, and physiological information about the tissue. These studies suggest that the GSRTM is necessary when receptor saturation exceeds 20% and highlight the potential for GSRTM to accurately measure receptor concentrations under saturation conditions, such as might be required during high dose drug studies, or for imaging applications where high concentrations of imaging agent are required to optimize signal-to-noise conditions. This model can also be applied to PET and SPECT imaging studies that tend to suffer from noisier data, but require one less parameter to fit if images are converted to imaging agent concentration (quantitative PET/SPECT).
Collapse
Affiliation(s)
- N Sadeghipour
- Biomedical Engineering, Illinois Institute of Technology, Chicago, IL 60616, USA
| | | | | |
Collapse
|
16
|
Tichauer KM, Wang Y, Pogue BW, Liu JTC. Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol 2015; 60:R239-69. [PMID: 26134619 PMCID: PMC4522156 DOI: 10.1088/0031-9155/60/14/r239] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The development of methods to accurately quantify cell-surface receptors in living tissues would have a seminal impact in oncology. For example, accurate measures of receptor density in vivo could enhance early detection or surgical resection of tumors via protein-based contrast, allowing removal of cancer with high phenotype specificity. Alternatively, accurate receptor expression estimation could be used as a biomarker to guide patient-specific clinical oncology targeting of the same molecular pathway. Unfortunately, conventional molecular contrast-based imaging approaches are not well adapted to accurately estimating the nanomolar-level cell-surface receptor concentrations in tumors, as most images are dominated by nonspecific sources of contrast such as high vascular permeability and lymphatic inhibition. This article reviews approaches for overcoming these limitations based upon tracer kinetic modeling and the use of emerging protocols to estimate binding potential and the related receptor concentration. Methods such as using single time point imaging or a reference-tissue approach tend to have low accuracy in tumors, whereas paired-agent methods or advanced kinetic analyses are more promising to eliminate the dominance of interstitial space in the signals. Nuclear medicine and optical molecular imaging are the primary modalities used, as they have the nanomolar level sensitivity needed to quantify cell-surface receptor concentrations present in tissue, although each likely has a different clinical niche.
Collapse
Affiliation(s)
- Kenneth M Tichauer
- Biomedical Engineering, Illinois Institute of Technology, Chicago IL 60616, USA
| | | | | | | |
Collapse
|
17
|
Direct characterization of arterial input functions by fluorescence imaging of exposed carotid artery to facilitate kinetic analysis. Mol Imaging Biol 2015; 16:488-94. [PMID: 24420443 DOI: 10.1007/s11307-013-0715-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
PURPOSE With the goal of facilitating tracer kinetic analysis in small-animal planar fluorescence imaging, an experimental method for characterizing tracer arterial input functions is presented. The proposed method involves exposing the common carotid arteries by surgical dissection, which can then be imaged directly during tracer injection and clearance. PROCEDURES Arterial concentration curves of IRDye-700DX-carboxylate, IRDye-800CW-EGF, and IRDye-800CW conjugated to anti-EGFR Affibody are recovered from athymic female mice (n = 12) by directly imaging exposed vessels. Images were acquired with two imaging protocols: a slow-kinetics approach (temporal resolution = 45 s) to recover the arterial curves from two tracers simultaneously, and a fast-kinetics approach (temporal resolution = 500 ms) to characterize the first-pass peak of a single tracer. Arterial input functions obtained by the carotid imaging technique, as well as plasma curves measured by blood sampling were fit with a biexponential pharmacokinetic model. RESULTS Pharmacological fast- and slow-phase rate constants recovered with the proposed method were 0.37 ± 0.26 and 0.007 ± 0.001 min(-1), respectively, for the IRDye700DX-C. For the IRDye800CW-EGF, the rate constants were 0.11 ± 0.13 and 0.003 ± 0.002 min(-1). These rate constants did not differ significantly from those calculated previously by blood sampling, as determined by an F test; however, the between-subject variability was four times lower for arterial curves recovered using the proposed technique, compared with blood sampling. CONCLUSIONS The proposed technique enables the direct characterization of arterial input functions for kinetic analysis. As this method requires no additional instrumentation, it is immediately deployable in commercially available planar fluorescence imaging systems.
Collapse
|
18
|
Holt RW, Demers JLH, Sexton KJ, Gunn JR, Davis SC, Samkoe KS, Pogue BW. Tomography of epidermal growth factor receptor binding to fluorescent Affibody in vivo studied with magnetic resonance guided fluorescence recovery in varying orthotopic glioma sizes. JOURNAL OF BIOMEDICAL OPTICS 2015; 20:26001. [PMID: 25652703 PMCID: PMC4317247 DOI: 10.1117/1.jbo.20.2.026001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Accepted: 12/23/2014] [Indexed: 05/20/2023]
Abstract
The ability to image targeted tracer binding to epidermal growth factor receptor (EGFR) was studied in vivo in orthotopically grown glioma tumors of different sizes. The binding potential was quantified using a dual-tracer approach, which employs a fluorescently labeled peptide targeted to EGFR and a reference tracer with similar pharmacokinetic properties but no specific binding, to estimate the relative bound fraction from kinetic compartment modeling. The recovered values of binding potential did not vary significantly as a function of tumor size (1 to 33 mm3), suggesting that binding potential may be consistent in the U251 tumors regardless of size or stage after implantation. However, the fluorescence yield of the targeted fluorescent tracers in the tumor was affected significantly by tumor size, suggesting that dual-tracer imaging helps account for variations in absolute uptake, which plague single-tracer imaging techniques. Ex vivo analysis showed relatively high spatial heterogeneity in each tumor that cannot be resolved by tomographic techniques. Nonetheless, the dual-tracer tomographic technique is a powerful tool for longitudinal bulk estimation of receptor binding.
Collapse
Affiliation(s)
- Robert W. Holt
- Dartmouth College, Department of Physics & Astronomy, Hanover, New Hampshire 03755, United States
| | - Jennifer-Lynn H. Demers
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States
| | - Kristian J. Sexton
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States
| | - Jason R. Gunn
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States
| | - Scott C. Davis
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States
| | - Kimberley S. Samkoe
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States
- Geisel School of Medicine at Dartmouth, Department of Surgery, Hanover, New Hampshire 03755, United States
| | - Brian W. Pogue
- Dartmouth College, Department of Physics & Astronomy, Hanover, New Hampshire 03755, United States
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States
- Geisel School of Medicine at Dartmouth, Department of Surgery, Hanover, New Hampshire 03755, United States
- Address all correspondence to: Brian W. Pogue, E-mail:
| |
Collapse
|
19
|
Samkoe KS, Tichauer KM, Gunn JR, Wells WA, Hasan T, Pogue BW. Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. Cancer Res 2014; 74:7465-74. [PMID: 25344226 PMCID: PMC4268352 DOI: 10.1158/0008-5472.can-14-0141] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
As receptor-targeted therapeutics become increasingly used in clinical oncology, the ability to quantify protein expression and pharmacokinetics in vivo is imperative to ensure successful individualized treatment plans. Current standards for receptor analysis are performed on extracted tissues. These measurements are static and often physiologically irrelevant; therefore, only a partial picture of available receptors for drug targeting in vivo is provided. Until recently, in vivo measurements were limited by the inability to separate delivery, binding, and retention effects, but this can be circumvented by a dual-tracer approach for referencing the detected signal. We hypothesized that in vivo receptor concentration imaging (RCI) would be superior to ex vivo immunohistochemistry (IHC). Using multiple xenograft tumor models with varying EGFR expression, we determined the EGFR concentration in each model using a novel targeted agent (anti-EGFR affibody-IRDye800CW conjugate) along with a simultaneously delivered reference agent (control affibody-IRDye680RD conjugate). The RCI-calculated in vivo receptor concentration was strongly correlated with ex vivo pathologist-scored IHC and computer-quantified ex vivo immunofluorescence. In contrast, no correlation was observed with ex vivo Western blot analysis or in vitro flow-cytometry assays. Overall, our results argue that in vivo RCI provides a robust measure of receptor expression equivalent to ex vivo immunostaining, with implications for use in noninvasive monitoring of therapy or therapeutic guidance during surgery.
Collapse
Affiliation(s)
- Kimberley S Samkoe
- Department of Surgery, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire. Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
| | - Kenneth M Tichauer
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois
| | - Jason R Gunn
- Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire
| | - Wendy A Wells
- Department of Pathology, Geisel School of Medicine at Dartmouth College, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
| | - Tayyaba Hasan
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Brian W Pogue
- Department of Surgery, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire. Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire
| |
Collapse
|
20
|
Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging. Nat Med 2014; 20:1348-53. [PMID: 25344739 PMCID: PMC4224611 DOI: 10.1038/nm.3732] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 07/03/2014] [Indexed: 12/24/2022]
Abstract
Lymph node biopsy (LNB) is employed in many cancer surgeries to identify metastatic disease and stage the cancer, yet morbidity and diagnostic delays associated with LNB could be avoided if non-invasive imaging of nodal involvement was reliable. Molecular imaging has potential in this regard; however, variable delivery and nonspecific uptake of imaging tracers has made conventional approaches ineffective clinically. A method of correcting for non-specific uptake with injection of a second untargeted tracer is presented, allowing tumor burden in lymph nodes to be quantified. The approach was confirmed in an athymic mouse model of metastatic human breast cancer targeting epidermal growth factor receptor, a cell surface receptor overexpressed by many cancers. A significant correlation was observed between in vivo (dual-tracer) and ex vivo measures of tumor burden (r = 0.97, p < 0.01), with an ultimate sensitivity of approximately 200 cells (potentially more sensitive than conventional LNB).
Collapse
|
21
|
Garbarino S, Caviglia G, Sambuceti G, Benvenuto F, Piana M. A novel description of FDG excretion in the renal system: application to metformin-treated models. Phys Med Biol 2014; 59:2469-84. [PMID: 24778350 DOI: 10.1088/0031-9155/59/10/2469] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This paper introduces a novel compartmental model describing the excretion of 18F-fluoro-deoxyglucose (FDG) in the renal system and a numerical method based on the maximum likelihood for its reduction. This approach accounts for variations in FDG concentration due to water re-absorption in renal tubules and the increase of the bladder's volume during the FDG excretion process. From the computational viewpoint, the reconstruction of the tracer kinetic parameters is obtained by solving the maximum likelihood problem iteratively, using a non-stationary, steepest descent approach that explicitly accounts for the Poisson nature of nuclear medicine data. The reliability of the method is validated against two sets of synthetic data realized according to realistic conditions. Finally we applied this model to describe FDG excretion in the case of animal models treated with metformin. In particular we show that our approach allows the quantitative estimation of the reduction of FDG de-phosphorylation induced by metformin.
Collapse
Affiliation(s)
- S Garbarino
- Dipartimento di Matematica, Università di Genova, via Dodecaneso 35, I-16146 Genova, Italy. CNR - SPIN Genova, via Dodecaneso 33, I-16146 Genova, Italy
| | | | | | | | | |
Collapse
|
22
|
Tichauer KM, Diop M, Elliott JT, Samkoe KS, Hasan T, St Lawrence K, Pogue BW. Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. Phys Med Biol 2014; 59:2341-51. [PMID: 24743262 DOI: 10.1088/0031-9155/59/10/2341] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Dual-tracer molecular imaging is a powerful approach to quantify receptor expression in a wide range of tissues by using an untargeted tracer to account for any nonspecific uptake of a molecular-targeted tracer. This approach has previously required the pharmacokinetics of the receptor-targeted and untargeted tracers to be identical, requiring careful selection of an ideal untargeted tracer for any given targeted tracer. In this study, methodology capable of correcting for tracer differences in arterial input functions, as well as binding-independent delivery and retention, is derived and evaluated in a mouse U251 glioma xenograft model using an Affibody tracer targeted to epidermal growth factor receptor (EGFR), a cell membrane receptor overexpressed in many cancers. Simulations demonstrated that blood, and to a lesser extent vascular-permeability, pharmacokinetic differences between targeted and untargeted tracers could be quantified by deconvolving the uptakes of the two tracers in a region of interest devoid of targeted tracer binding, and therefore corrected for, by convolving the uptake of the untargeted tracer in all regions of interest by the product of the deconvolution. Using fluorescently labeled, EGFR-targeted and untargeted Affibodies (known to have different blood clearance rates), the average tumor concentration of EGFR in four mice was estimated using dual-tracer kinetic modeling to be 3.9 ± 2.4 nM compared to an expected concentration of 2.0 ± 0.4 nM. However, with deconvolution correction a more equivalent EGFR concentration of 2.0 ± 0.4 nM was measured.
Collapse
Affiliation(s)
- K M Tichauer
- Biomedical Engineering, Illinois Institute of Technology, Chicago, IL 60616, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Hamzei N, Samkoe KS, Elliott JT, Holt RW, Gunn JR, Hasan T, Pogue BW, Tichauer KM. Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors. AUSTIN JOURNAL OF BIOMEDICAL ENGINEERING 2014; 1:austinpublishinggroup.com/biomedical-engineering/fulltext/ajbe-v1-id1002.php. [PMID: 25414912 PMCID: PMC4235770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Molecular differences between cancerous and healthy tissue have become key targets for novel therapeutics specific to tumor receptors. However, cancer cell receptor expression can vary within and amongst different tumors, making strategies that can quantify receptor concentration in vivo critical for the progression of targeted therapies. Recently a dual-tracer imaging approach capable of providing quantitative measures of receptor concentration in vivo was developed. It relies on the simultaneous injection and imaging of receptor-targeted tracer and an untargeted tracer (to account for non-specific uptake of the targeted tracer). Early implementations of this approach have been structured on existing "reference tissue" imaging methods that have not been optimized for or validated in dual-tracer imaging. Using simulations and mouse tumor model experimental data, the salient findings in this study were that all widely used reference tissue kinetic models can be used for dual-tracer imaging, with the linearized simplified reference tissue model offering a good balance of accuracy and computational efficiency. Moreover, an alternate version of the full two-compartment reference tissue model can be employed accurately by assuming that the K1s of the targeted and untargeted tracers are similar to avoid assuming an instantaneous equilibrium between bound and free states (made by all other models).
Collapse
Affiliation(s)
- Nazanin Hamzei
- Biomedical Engineering Despartment, Illinois Institute of Technology, Chicago IL 60616, USA
| | - Kimberley S Samkoe
- Thayer School of Engineering, Dartmouth College, Hanover NH 03755, USA
- Department of Surgery, Dartmouth Medical School, Hanover NH 03755, USA
| | | | - Robert W Holt
- Thayer School of Engineering, Dartmouth College, Hanover NH 03755, USA
| | - Jason R Gunn
- Thayer School of Engineering, Dartmouth College, Hanover NH 03755, USA
| | - Tayyaba Hasan
- Wellman Center for Photo medicine, Massachusetts General Hospital, Boston MA 02114, USA
| | - Brian W Pogue
- Thayer School of Engineering, Dartmouth College, Hanover NH 03755, USA
- Department of Surgery, Dartmouth Medical School, Hanover NH 03755, USA
- Wellman Center for Photo medicine, Massachusetts General Hospital, Boston MA 02114, USA
| | - Kenneth M Tichauer
- Biomedical Engineering Despartment, Illinois Institute of Technology, Chicago IL 60616, USA
| |
Collapse
|
24
|
Tichauer KM, Deharvengt SJ, Samkoe KS, Gunn JR, Bosenberg MW, Turk MJ, Hasan T, Stan RV, Pogue BW. Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol 2013; 16:372-82. [PMID: 24217944 DOI: 10.1007/s11307-013-0692-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Revised: 09/05/2013] [Accepted: 09/19/2013] [Indexed: 12/28/2022]
Abstract
PURPOSE Cancer-specific endothelial markers available for intravascular binding are promising targets for new molecular therapies. In this study, a molecular imaging approach of quantifying endothelial marker concentrations (EMCI) is developed and tested in highly light-absorbing melanomas. The approach involves injection of targeted imaging tracer in conjunction with an untargeted tracer, which is used to account for nonspecific uptake and tissue optical property effects on measured targeted tracer concentrations. PROCEDURES Theoretical simulations and a mouse melanoma model experiment were used to test out the EMCI approach. The tracers used in the melanoma experiments were fluorescently labeled anti-Plvap/PV1 antibody (plasmalemma vesicle associated protein Plvap/PV1 is a transmembrane protein marker exposed on the luminal surface of endothelial cells in tumor vasculature) and a fluorescent isotype control antibody, the uptakes of which were measured on a planar fluorescence imaging system. RESULTS The EMCI model was found to be robust to experimental noise under reversible and irreversible binding conditions and was capable of predicting expected overexpression of PV1 in melanomas compared to healthy skin despite a 5-time higher measured fluorescence in healthy skin compared to melanoma: attributable to substantial light attenuation from melanin in the tumors. CONCLUSIONS This study demonstrates the potential of EMCI to quantify endothelial marker concentrations in vivo, an accomplishment that is currently unavailable through any other methods, either in vivo or ex vivo.
Collapse
Affiliation(s)
- Kenneth M Tichauer
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA,
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Garai E, Sensarn S, Zavaleta CL, Van de Sompel D, Loewke NO, Mandella MJ, Gambhir SS, Contag CH. High-sensitivity, real-time, ratiometric imaging of surface-enhanced Raman scattering nanoparticles with a clinically translatable Raman endoscope device. JOURNAL OF BIOMEDICAL OPTICS 2013; 18:096008. [PMID: 24008818 PMCID: PMC3763230 DOI: 10.1117/1.jbo.18.9.096008] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Revised: 07/24/2013] [Accepted: 07/31/2013] [Indexed: 05/19/2023]
Abstract
Topical application and quantification of targeted, surface-enhanced Raman scattering (SERS) nanoparticles offer a new technique that has the potential for early detection of epithelial cancers of hollow organs. Although less toxic than intravenous delivery, the additional washing required to remove unbound nanoparticles cannot necessarily eliminate nonspecific pooling. Therefore, we developed a real-time, ratiometric imaging technique to determine the relative concentrations of at least two spectrally unique nanoparticle types, where one serves as a nontargeted control. This approach improves the specific detection of bound, targeted nanoparticles by adjusting for working distance and for any nonspecific accumulation following washing. We engineered hardware and software to acquire SERS signals and ratios in real time and display them via a graphical user interface. We report quantitative, ratiometric imaging with nanoparticles at pM and sub-pM concentrations and at varying working distances, up to 50 mm. Additionally, we discuss optimization of a Raman endoscope by evaluating the effects of lens material and fiber coating on background noise, and theoretically modeling and simulating collection efficiency at various working distances. This work will enable the development of a clinically translatable, noncontact Raman endoscope capable of rapidly scanning large, topographically complex tissue surfaces for small and otherwise hard to detect lesions.
Collapse
Affiliation(s)
- Ellis Garai
- Stanford University, Department of Mechanical Engineering, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
| | - Steven Sensarn
- Stanford University, Department of Radiology, Stanford, California 94305
- Stanford University, Department of Pediatrics, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
| | - Cristina L. Zavaleta
- Stanford University, Department of Radiology, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
| | - Dominique Van de Sompel
- Stanford University, Department of Radiology, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
| | - Nathan O. Loewke
- Stanford University, Department of Electrical Engineering, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
| | - Michael J. Mandella
- Stanford University, Department of Pediatrics, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
| | - Sanjiv S. Gambhir
- Stanford University, Department of Radiology, Stanford, California 94305
- Stanford University, Departments of Bioengineering and Materials Science and Engineering, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
- Address all correspondence to: Sanjiv S. Gambhir, Stanford University, 318 Campus Drive, Clark Center, Rm E150, Stanford, California, 94305. E-mail: ; Christopher H. Contag, Stanford University, 318 Campus Drive, Clark Center, Rm E150, Stanford, California, 94305. Tel: 650-725-6583; Fax: (650) 498-7723; E-mail:
| | - Christopher H. Contag
- Stanford University, Department of Radiology, Stanford, California 94305
- Stanford University, Department of Pediatrics, Stanford, California 94305
- Stanford University, Department of Microbiology & Immunology, Stanford, California 94305
- Stanford University, Molecular Imaging Program at Stanford, Stanford, California 94305
- Address all correspondence to: Sanjiv S. Gambhir, Stanford University, 318 Campus Drive, Clark Center, Rm E150, Stanford, California, 94305. E-mail: ; Christopher H. Contag, Stanford University, 318 Campus Drive, Clark Center, Rm E150, Stanford, California, 94305. Tel: 650-725-6583; Fax: (650) 498-7723; E-mail:
| |
Collapse
|
26
|
Tichauer KM, Holt RW, El-Ghussein F, Davis SC, Samkoe KS, Gunn JR, Leblond F, Pogue BW. Dual-tracer background subtraction approach for fluorescent molecular tomography. JOURNAL OF BIOMEDICAL OPTICS 2013; 18:16003. [PMID: 23292612 PMCID: PMC3537325 DOI: 10.1117/1.jbo.18.1.016003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Diffuse fluorescence tomography requires high contrast-to-background ratios to accurately reconstruct inclusions of interest. This is a problem when imaging the uptake of fluorescently labeled molecularly targeted tracers in tissue, which can result in high levels of heterogeneously distributed background uptake. We present a dual-tracer background subtraction approach, wherein signal from the uptake of an untargeted tracer is subtracted from targeted tracer signal prior to image reconstruction, resulting in maps of targeted tracer binding. The approach is demonstrated in simulations, a phantom study, and in a mouse glioma imaging study, demonstrating substantial improvement over conventional and homogenous background subtraction image reconstruction approaches.
Collapse
Affiliation(s)
- Kenneth M. Tichauer
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
| | - Robert W. Holt
- Dartmouth College, Department of Physics and Astronomy, Hanover, New Hampshire 03755
| | - Fadi El-Ghussein
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
| | - Scott C. Davis
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
| | - Kimberley S. Samkoe
- Dartmouth Medical School, Department of Surgery, Lebanon, New Hampshire 03756
| | - Jason R. Gunn
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
| | - Frederic Leblond
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
- ÉcolePolytechnique Montréal, Génie Physique, Montréal, Quebec H3C 3A7, Canada
| | - Brian W. Pogue
- Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
- Dartmouth College, Department of Physics and Astronomy, Hanover, New Hampshire 03755
- Dartmouth Medical School, Department of Surgery, Lebanon, New Hampshire 03756
- Address all correspondence to: Brian W. Pogue, Dartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755. Tel: 603-646-3861; Fax: 603-646-3856; E-mail:
| |
Collapse
|